For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker has been permanently closed/terminated.
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
Sites may record protocol training in the centre admin menu of the CCTG Site Training Utility (STU). CCTG has offered protocol-specific training for sites since 2012. To continue to be GCP compliant, protocol training has been required for all participants with delegated duties on the trial participants list for all new trials centrally activated after July 1, 2018. This requirement is stated in the Central Activation Letter and Notice of Health Canada Submission
Registration for the 2019 Canadian Cancer Research Conference (CCRC) is now open.The conference will be of interest to cancer researchers, clinicians, and decision-makers across disciplines and at all stages of their career.
The Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) was published online today, August 20, 2019 and can be found on the Health Canada website at:
CCTG Director, Dr Janet Dancey will be a Keynote Speaker at the The 5th International Clinical Trials Methodology Conference is being held 6-9th October 2019 in Brighton UK. Dr Dancey will be speaking on the The Evolution of Academic Sponsored Clinical Trials in the 21st Century: Lessons Learned at the Canadian Cancer Trials Group.
The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to:
Carol is a cancer survivor who was treated for metastatic gynecologic cancer in 2013. She has a network of other cancer survivors and patients who support each other during their cancer journeys. Today, Carol is currently a CCTG patient representative for the CCTG Gynecology, Economic Analysis and Clinical Trials committees. Carol is also the Managing Director, Audit Services at Ontario Teachers Pension Plan. Her career has included roles in finance, information technology, investments, risk management, external audit and (now) internal audit.
